EN

Dziękujemy, Jerzy Kowalski

Wkrótce się z Tobą skontaktujemy.

Chemia & Biochemia

Newsletter

ADME Database

ADME Database is a database containing the latest and most comprehensive data on interactions of substances with Drug Metabolizing Enzymes and Drug Transporters. It is designed for use in drug research and development, including drug-drug interactions and ADME (Absorption, Distribution, Metabolism and Excretion) studies.

The information is organized by category (therapeutic area), drug name, enzyme, reaction, and type. ADME DB is supported by chemical/metabolite structures as well as kinetic values found in the literature.

The database is available online and completely searchable by keywords or chemical structures. Advanced searches are also available to support investigational studies on drug-drug interactions.

ADME DB Contains more than 26 000 substances, a number of natural products and preparations, as well as other factors influencing Drug Metabolizing Enzymes activity. Contains data collected from more than 18 000 citations.
Database Structure
ADME Database contains information on CYP and other Phase I and Phase II enzymes and a number of variants, which significantly contribute/are tested in the metabolism of xenobiotics (drugs and other chemicals) and endobiotics in humans in vitro and in vivo.



ADMEBD contains three sub-databases:
  • Drug Metabolizing Enzymes Database:
    • Provides information on specific interactions for a given substance with Human Phase I Enzymes such as P450 (CYP), FMO, AKR, MAO and AO; Human Phase II Enzymes such as Esterases, UGT, GST, and SULT.
    • Contains over 72 800 entries for CYPs and about 15 400 for other enzymes.
  • Kinetic Metabolism Database:
    • Database contains entries extracted from Human Cytochrome P450 metabolism database references providing numerical data on major kinetic parameters relevant for use in drug developing/application studies.
  • Transporters Database:
    • Provides information on more than 400 Transporters (including ABCs, OATPs, OCTs, OATs, SLCs) involved in drugs transport, physiological compounds, nutrients, and other chemicals and metabolites.
    • Contains over 34 000 entries.



Detailed information for each entry includes the following data items:
  • Protein information about either enzyme/transporter.
  • Metabolic reaction.
  • Interaction type (substrate, inhibitor, inducer, activator).
  • Drug/Metabolite structure.
  • References linked to PubMed.
  • Kinetic information: in vitro assay model, Km, Vmax, Ki, Ks, Efficiency, IC50, EC50, t1/2 and more.

 
Benefits
  • Reduce the costs - since the service is available online, it is accessible anywhere via a web browser. As a result, there is no need to pay for expensive initial cost associated with package software.
  • Instant access - upon subscription and receiving a user ID and a password, users are able to login to the system on a 24×7 operating basis throughout the entire year (excluding system maintenance periods).
  • No maintenance/management fees - there is no need to setup a dedicated server within the company. This eliminates the need for maintenance, management, regular data backups, and updates.
  • High security - with Fujitsu's high security measures being implemented, there is no need to worry about data loss and information leaks.

 
Examples and Applications
  • Evaluating and predicting clinical side effects and interactions of known and new drugs/chemicals/physiological compounds.
  • Computer assisted development of new drugs and pro-drugs.
  • Selecting CYP-selective substrates/inhibitors for in vivo and in vitro studies.
  • Studying properties of natural and artificial CYP mutants using selective metabolic reactions.



 
Clinical DDI
Clinical Drug-Drug Interactions Database is a part of ADMEDB designed for scientists and clinicians working in the field of drug development and drug-drug interactions. Database includes material continuously analyzed and added from publications.



Clinical Drug-Drug Interactions Database contains following parameters:
  • Drug Metabolizing Enzyme.
  • Substrate (victim drug).
  • Inhibitor (perpetrator).
  • Dosage Regimen.
  • AUC Ratio.
  • Half-life (t1/2) Ratio.
  • Maximum concentration in blood (Cmax) Ratio.



 

ADME Database

ADME Database is a database containing the latest and most comprehensive data on interactions of substances with Drug Metabolizing Enzymes and Drug Transporters. It is designed for use in drug research and development, including drug-drug interactions and ADME (Absorption, Distribution, Metabolism and Excretion) studies.

The information is organized by category (therapeutic area), drug name, enzyme, reaction, and type. ADME DB is supported by chemical/metabolite structures as well as kinetic values found in the literature.

The database is available online and completely searchable by keywords or chemical structures. Advanced searches are also available to support investigational studies on drug-drug interactions.

ADME DB Contains more than 26 000 substances, a number of natural products and preparations, as well as other factors influencing Drug Metabolizing Enzymes activity. Contains data collected from more than 18 000 citations.
ADME Database contains information on CYP and other Phase I and Phase II enzymes and a number of variants, which significantly contribute/are tested in the metabolism of xenobiotics (drugs and other chemicals) and endobiotics in humans in vitro and in vivo.



ADMEBD contains three sub-databases:
  • Drug Metabolizing Enzymes Database:
    • Provides information on specific interactions for a given substance with Human Phase I Enzymes such as P450 (CYP), FMO, AKR, MAO and AO; Human Phase II Enzymes such as Esterases, UGT, GST, and SULT.
    • Contains over 72 800 entries for CYPs and about 15 400 for other enzymes.
  • Kinetic Metabolism Database:
    • Database contains entries extracted from Human Cytochrome P450 metabolism database references providing numerical data on major kinetic parameters relevant for use in drug developing/application studies.
  • Transporters Database:
    • Provides information on more than 400 Transporters (including ABCs, OATPs, OCTs, OATs, SLCs) involved in drugs transport, physiological compounds, nutrients, and other chemicals and metabolites.
    • Contains over 34 000 entries.



Detailed information for each entry includes the following data items:
  • Protein information about either enzyme/transporter.
  • Metabolic reaction.
  • Interaction type (substrate, inhibitor, inducer, activator).
  • Drug/Metabolite structure.
  • References linked to PubMed.
  • Kinetic information: in vitro assay model, Km, Vmax, Ki, Ks, Efficiency, IC50, EC50, t1/2 and more.

 
  • Reduce the costs - since the service is available online, it is accessible anywhere via a web browser. As a result, there is no need to pay for expensive initial cost associated with package software.
  • Instant access - upon subscription and receiving a user ID and a password, users are able to login to the system on a 24×7 operating basis throughout the entire year (excluding system maintenance periods).
  • No maintenance/management fees - there is no need to setup a dedicated server within the company. This eliminates the need for maintenance, management, regular data backups, and updates.
  • High security - with Fujitsu's high security measures being implemented, there is no need to worry about data loss and information leaks.

 
  • Evaluating and predicting clinical side effects and interactions of known and new drugs/chemicals/physiological compounds.
  • Computer assisted development of new drugs and pro-drugs.
  • Selecting CYP-selective substrates/inhibitors for in vivo and in vitro studies.
  • Studying properties of natural and artificial CYP mutants using selective metabolic reactions.



 
Clinical Drug-Drug Interactions Database is a part of ADMEDB designed for scientists and clinicians working in the field of drug development and drug-drug interactions. Database includes material continuously analyzed and added from publications.



Clinical Drug-Drug Interactions Database contains following parameters:
  • Drug Metabolizing Enzyme.
  • Substrate (victim drug).
  • Inhibitor (perpetrator).
  • Dosage Regimen.
  • AUC Ratio.
  • Half-life (t1/2) Ratio.
  • Maximum concentration in blood (Cmax) Ratio.